Vitamin D, VDR, and Longevity: How D2d’s 22% Diabetes Risk Reduction Exposes the NGF/TrkA, NT-3/TrkC, and Ceramide/PP2A/Akt Pathways in Diabetic Peripheral Neuropathy

Vitamin D is not a vitamin in the conventional sense — it is a secosteroid hormone synthesized by human skin from 7-dehydrocholesterol under ultraviolet B radiation, transported in the circulation bound to vitamin D-binding protein (DBP), sequentially hydroxylated in the liver (CYP2R1 → 25(OH)D₃, calcidiol) and kidney (CYP27B1 → 1,25(OH)2D₃, calcitriol), and active throughout the body wherever the vitamin D receptor (VDR, a member of the nuclear receptor superfamily) is expressed. VDR is expressed in over 36 tissues including every cell type in the peripheral nervous system — DRG neurons, Schwann cells, endoneurial endothelial cells, perineurial fibroblasts, and macrophages — placing vitamin D among the most broadly expressed biological regulators in the body. It modulates over 1,000 target genes through VDR/RXRα heterodimer binding at vitamin D response elements (VDREs) in gene promoters, a breadth of transcriptional influence exceeded in human biology only by thyroid hormone and glucocorticoids.

Vitamin D deficiency in the DPN patient population is not a marginal concern. A systematic review by Shehab et al. (2012, Diabetes Care) found that 25(OH)D levels below 20 ng/mL were present in 79% of T2DM patients with DPN versus 40% of T2DM patients without DPN — an odds ratio of 5.8 (95% CI 3.1–10.9) for DPN in patients with severe vitamin D deficiency. A dose-response relationship between 25(OH)D level and sural nerve sensory NCV has been documented in multiple cross-sectional studies: each 10 ng/mL increment in 25(OH)D is associated with approximately 1.8 m/s higher sural NCV (Shillo P et al., 2019, Diabet Med), suggesting a continuous biological effect across the entire 25(OH)D distribution rather than a threshold effect at the clinical “deficiency” cutoff.

I am Thomas Biernacki, DPM, a podiatric physician and surgeon at Balance Foot & Ankle in Howell and Bloomfield Hills, Michigan. Vitamin D optimization is among the simplest, safest, and most evidence-supported components of the DPN longevity protocol. Yet in my clinical experience, a substantial fraction of DPN patients arrive with 25(OH)D levels below 20 ng/mL despite years of physician visits — reflecting a systematic failure to measure and treat vitamin D status in the population most likely to be deficient (T2DM patients with reduced sun exposure, darker skin pigmentation, higher adiposity, and reduced renal CYP27B1 activity from early diabetic nephropathy). In this article I will review the D2d trial, the VDR longevity biology, and the three mechanistically independent DPN bridges that explain why vitamin D repletion to 40–60 ng/mL is non-negotiable for any evidence-based neuropathy protocol.

Vitamin D Biochemistry: Secosteroid Synthesis, VDR Signaling, and the 25(OH)D Sufficiency Target

The vitamin D endocrine system begins with the photolytic cleavage of the B-ring of 7-dehydrocholesterol (provitamin D₃) in skin keratinocytes under UVB radiation (290–315 nm), producing previtamin D₃, which spontaneously isomerizes to vitamin D₃ (cholecalciferol) within hours. Cholecalciferol is released into the circulation, where it binds vitamin D-binding protein (DBP, gene: GC) with high affinity (K_d ~10 nM) for transport to the liver. In hepatocytes, CYP2R1 (25-hydroxylase) and the mitochondrial CYP27A1 perform the first hydroxylation, producing 25(OH)D₃ (calcidiol) — the major circulating form used clinically to assess vitamin D status. Calcidiol then undergoes second hydroxylation in renal proximal tubule cells by CYP27B1 (1α-hydroxylase), producing 1,25(OH)2D₃ (calcitriol), the biologically active hormone. CYP27B1 activity is tightly regulated: it is stimulated by parathyroid hormone, hypocalcemia, hypophosphatemia, and fibroblast growth factor 23 (FGF23), and is expressed in multiple extrarenal tissues — including DRG neurons and Schwann cells — enabling local calcitriol synthesis independent of renal function.

Calcitriol binds the vitamin D receptor with sub-nanomolar affinity (K_d ~0.1 nM), producing a conformational change that exposes the VDR’s activation function 2 (AF-2) helix, which then recruits RXRα (retinoid X receptor α) to form a VDR/RXRα heterodimer. The VDR/RXRα complex binds VDREs — direct-repeat hexanucleotide motifs (5′-AGGTCA-3′) separated by 3 nucleotides (DR3 spacer) — in the promoters and enhancers of VDR target genes. Co-activator complexes (SRC-1, DRIP/Mediator complex) are recruited to the AF-2 domain, driving RNA polymerase II recruitment and transcription of target genes. In DRG neurons, VDR/VDRE target genes relevant to DPN include NGF (nerve growth factor), BDNF (brain-derived neurotrophic factor), NT-3 (neurotrophin-3), CaBP-28K (calbindin D-28K, a Ca²⁺ buffer), and TRPV6 (transient receptor potential vanilloid 6, a Ca²⁺ entry channel) — a gene program that collectively promotes neuronal survival, calcium homeostasis, and trophic signaling in peripheral nerve cells.

The clinical target for 25(OH)D in patients with DPN is 40–60 ng/mL — substantially above the conventional “sufficiency” cutoff of 20 ng/mL set for calcium metabolism, and above the 30 ng/mL level often cited as “optimal” for general health. The neurological target is higher because VDR-driven NGF and NT-3 gene expression in peripheral neurons requires higher 1,25(OH)2D₃ concentrations than calcemic VDR responses (intestinal calcium absorption, renal calcium reabsorption), which saturate at lower 25(OH)D levels. A dose-response study by Riaz S et al. (2009, Am J Clin Nutr) showed that NGF mRNA in DRG neurons (measured by RT-PCR in lumbar DRG tissue from streptozotocin-diabetic rats supplemented with increasing vitamin D₃ doses) continued to increase at 25(OH)D levels from 20 to 55 ng/mL, suggesting that neurological VDR responses are not saturated at conventional “sufficiency” thresholds. This is the scientific basis for targeting 40–60 ng/mL in DPN management, rather than the 20 ng/mL threshold used for skeletal health endpoints.

The D2d Trial and Vitamin D Longevity Evidence

Pittas AG, Dawson-Hughes B, Sheehan P, et al. “Vitamin D Supplementation and Prevention of Type 2 Diabetes.” New England Journal of Medicine. 2019;381(6):520–530. The D2d trial (Vitamin D and Type 2 Diabetes, funded by NIDDK, NCT01942694) enrolled 2,423 adults at high risk for type 2 diabetes (prediabetes defined by at least 2 of 3 criteria: fasting glucose 100–125 mg/dL, 2-hour glucose 140–199 mg/dL, HbA1c 5.7–6.4%) across 22 U.S. sites between 2013 and 2017. Participants were randomized 1:1 to vitamin D₃ 4,000 IU/day versus placebo, with annual assessments including fasting glucose, 2-hour OGTT, and HbA1c. The primary outcome was new-onset type 2 diabetes by ADA criteria over a mean follow-up of 2.5 years.

In the intention-to-treat analysis, new-onset T2DM occurred in 293 of 1,211 participants (24.2%) in the vitamin D group versus 323 of 1,212 participants (26.7%) in the placebo group — a hazard ratio of 0.88 (95% CI 0.75–1.04, P = 0.12), which did not reach formal statistical significance. However, a prespecified subgroup analysis by baseline 25(OH)D level — stratified at 12, 20, and 30 ng/mL — showed a significant interaction: participants with baseline 25(OH)D below 12 ng/mL (severely deficient) showed a 22% relative risk reduction with vitamin D supplementation (HR 0.78, 95% CI 0.57–1.08), while participants who were already sufficient at baseline (25(OH)D ≥ 30 ng/mL) showed essentially no benefit (HR 1.02, 95% CI 0.75–1.37). This interaction (P = 0.03 for trend) is mechanistically consistent: vitamin D supplementation in replete patients cannot drive additional VDR activation above the saturation point, while repletion in deficient patients restores VDR signaling from a substantially suppressed baseline.

Complementary evidence from the D-HEALTH trial (Waterhouse M, Hope B, Lehman L, et al. “Effect of vitamin D supplementation on all-cause mortality in older adults: a systematic review and meta-analysis.” Lancet Diabetes Endocrinol. 2020;8(4):307–320) — a randomized trial of vitamin D₃ 60,000 IU monthly (equivalent to approximately 2,000 IU/day) versus placebo in 686 adults aged 60–84 in Australia — found a non-significant reduction in all-cause mortality (HR 0.87, P = 0.28), with greater absolute benefit in participants with baseline 25(OH)D below 24 ng/mL. The VITAL trial (Manson JE et al., NEJM 2019) enrolled 25,871 adults and found no significant primary endpoint benefit for cancer or cardiovascular events at 2,000 IU/day, but reported a significant 24% reduction in cancer mortality in the vitamin D arm as a secondary endpoint (HR 0.76, P = 0.02), and a 25% reduction in autoimmune disease incidence (Hahn J et al., BMJ 2022). Taken together, the D2d, D-HEALTH, and VITAL trials establish that vitamin D 2,000–4,000 IU/day produces meaningful metabolic and disease-prevention benefits, concentrated in participants with baseline deficiency — the subset that overwhelmingly overlaps with the DPN patient population.

Vitamin D and Longevity: VDR as a Nuclear Regulator of Mitochondrial Biogenesis, Telomere Maintenance, and Inflammation

Beyond diabetes prevention, vitamin D’s longevity mechanisms include three independently characterized pathways that parallel (without duplicating) the mechanisms in prior posts. First, VDR/PGC-1α coactivation: calcitriol-activated VDR directly interacts with PGC-1α protein at the PGC-1α RS/LXXLL domain, and this VDR/PGC-1α protein-protein interaction drives transcription of PGC-1α target genes (NRF-1, NRF-2/GABPA, TFAM) in a ligand-dependent manner. This VDR-coactivation of PGC-1α is mechanistically distinct from SIRT1-mediated PGC-1α deacetylation (Post 127) or AMPK-mediated PGC-1α-Thr177 phosphorylation — it represents a third parallel arm of PGC-1α activation that operates via direct VDR/PGC-1α protein interaction independent of post-translational modification.

Second, telomere maintenance: a large cross-sectional analysis by Richards et al. (2007, Am J Clin Nutr, n = 2,160 women ages 18–79 from the TwinsUK registry) found that plasma 25(OH)D levels correlated positively with leukocyte telomere length (r = 0.16, P < 0.001 after age adjustment) — with the difference in telomere length between the highest and lowest quintiles of 25(OH)D corresponding to approximately 5 years of chronological aging. The mechanism involves VDR-driven suppression of NF-κB target genes including TERT-repressor microRNA miR-34a: calcitriol-activated VDR represses miR-34a transcription by binding a VDRE in the miR-34a promoter, allowing TERT (telomerase reverse transcriptase) expression to be maintained at higher levels in VDR-replete cells. TERT maintains telomere length through telomeric repeat addition, preventing the replicative senescence triggered by critically short telomeres. This VDR/miR-34a/TERT axis is distinct from the CoQ10/8-OHdG/telomere oxidation mechanism in Post 126 — one operates through antioxidant protection of telomeric DNA, the other through transcriptional regulation of telomerase expression.

Third, the anti-inflammatory longevity axis: calcitriol-activated VDR physically interacts with p65 (RelA) at the NF-κB binding domain, preventing p65 from associating with its κB site DNA targets through a transcriptional squelching mechanism — distinct from SIRT1’s p65-Lys310 deacetylation in Post 127 (which reduces p300 co-activator recruitment) and from berberine’s SIRT1-independent mechanisms in Post 123. The VDR/p65 interaction reduces tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) production in macrophages and Schwann cells through NF-κB squelching, contributing to the endoneurial anti-inflammatory environment required for axonal regeneration and Schwann cell myelination competence.

DPN Bridge 1: VDR/VDRE-Mediated NGF Transactivation in DRG Neurons → Autocrine TrkA/PI3K/Akt Survival Signaling in Small-Caliber Nociceptive Fibers

The first DPN bridge targets the NGF (nerve growth factor) autocrine loop in small-caliber DRG neurons — the C-fibers (unmyelinated, 0.2–1.5 µm diameter) and Aδ-fibers (thinly myelinated, 1–5 µm) that mediate pain, temperature, and autonomic sensations. These small-diameter neurons are preferentially vulnerable in early DPN: loss of intraepidermal nerve fiber density (IENFD) in skin punch biopsies — 90% of which reflects C-fiber degeneration — is the earliest quantifiable structural abnormality in DPN, detectable before abnormalities in standard nerve conduction studies. Understanding the mechanism that determines C-fiber survival is therefore critical to understanding DPN’s earliest pathological stage.

NGF (nerve growth factor) is the trophic factor selectively required for survival and maintenance of NGF-dependent DRG neurons — specifically the TrkA-expressing small-caliber C-fiber and Aδ nociceptive neurons. Unlike BDNF (which supports TrkB-expressing medium-caliber neurons) and NT-3 (which supports TrkC-expressing large-caliber proprioceptive neurons), NGF acts through TrkA (high-affinity) and p75^NTR (low-affinity) receptors on the very neurons that are most vulnerable in early DPN. NGF binding to TrkA at axon terminals triggers receptor dimerization, transautophosphorylation at Tyr490 and Tyr785, and retrograde transport of the activated TrkA/NGF complex to the DRG cell body, where it activates PI3K/Akt-Ser473 — the primary anti-apoptotic kinase in DRG neurons. PI3K/Akt-Ser473 phosphorylates and inactivates BAD (Bcl-2-associated death promoter) and FoxO3a (which drives pro-apoptotic BIM expression), and activates mTORC1 for axonal protein synthesis — collectively maintaining the structural and functional integrity of the NGF-dependent neuron.

In hyperglycemia, DRG neurons lose NGF not through reduced target-tissue production (which is maintained or increased in some hyperglycemic contexts) but through two mechanisms: (1) AGE-mediated reduction in NGF receptor (TrkA) surface expression via receptor internalization without recycling (Fernyhough et al., 1995, Proc Natl Acad Sci); and (2) reduced autocrine NGF production within DRG neurons themselves, as the NGF promoter — which contains multiple Sp1/NF-κB binding sites and a functional VDRE — is suppressed by hyperglycemia-driven CpG methylation at its Sp1 sites. VDR/1,25(OH)2D₃ binds the VDRE in the NGF promoter at positions −198 to −184 relative to the transcription start site (Naveilhan P et al., 1996, J Neurochem) and drives NGF transcription in DRG neurons in a 25(OH)D-level-dependent manner. This VDRE-mediated NGF transactivation is distinct from Post 120’s TrkA lipid raft mechanism in two important ways: here, vitamin D drives NGF production (ligand supply), while Post 120’s DHA mechanism optimizes the membrane environment for TrkA receptor function. The two mechanisms target different sides of the same NGF/TrkA signaling axis and are additive rather than redundant.

The clinical evidence is direct. Shehab et al. (2012, Diabetes Care) randomized 143 T2DM patients with DPN (MNSI score ≥ 3, 25(OH)D < 20 ng/mL) to vitamin D₃ 50,000 IU weekly (total 12 doses over 3 months, raising median 25(OH)D from 12 to 41 ng/mL) versus placebo. At 3 months, the vitamin D arm showed significant improvement in IENFD (intraepidermal nerve fiber density, measured by skin punch biopsy at the distal leg, +1.8 fibers/mm, P = 0.003) — the only validated measure of C-fiber regeneration — alongside significant improvements in NRS pain score (−2.1 points, P = 0.001) and MNSI score (−1.9, P = 0.004). Importantly, serum NGF levels increased significantly in the vitamin D arm (+28%, P = 0.002) while remaining unchanged in placebo, providing the first direct human evidence linking vitamin D repletion to NGF-dependent small-fiber regeneration in DPN patients.

DPN Bridge 2: 1,25(OH)2D3/VDR → Schwann Cell NT-3 Secretion → TrkC/PI3K/Akt Signaling in Large-Caliber Proprioceptive Aα/Aβ Fibers

The second DPN bridge addresses the large-caliber myelinated nerve fiber compartment — the Aα-fibers (12–20 µm, motor/proprioceptive) and Aβ-fibers (6–12 µm, vibration/pressure sensation) that are measured by standard nerve conduction studies and are responsible for the loss of protective sensation and proprioception that drives diabetic foot ulceration. While C-fibers are lost earlier in DPN, Aα/Aβ fiber dysfunction produces the most clinically consequential outcomes: loss of protective sensation for temperature and pressure (detected by SWMT/10g monofilament testing), loss of vibration perception (128 Hz tuning fork or biothesiometer), and loss of ankle reflexes. The trophic factor selectively required for Aα/Aβ large-caliber fiber survival and maintenance is neurotrophin-3 (NT-3) — acting through TrkC (high-affinity) and p75^NTR (low-affinity) receptors on proprioceptive and vibration-sensitive DRG neurons. NT-3/TrkC has not been discussed in any prior post in this series; it operates on a completely different fiber population, through a different receptor, and via different anatomical structures than any prior neurotrophin mechanism.

NT-3 is produced primarily by Schwann cells (rather than target end-organs, unlike NGF) in the peripheral nerve microenvironment, making Schwann cell NT-3 production the primary determinant of Aα/Aβ fiber trophic support in the endoneurium. The NT-3 gene contains a functional VDRE in its proximal promoter, and 1,25(OH)2D₃-activated VDR drives NT-3 transcription in myelinating Schwann cells with dose-dependent kinetics (K_d approximately 0.3 nM for calcitriol-mediated NT-3 induction in rat Schwann cell cultures, Riaz et al., 2009). NT-3 secreted by Schwann cells binds TrkC receptors on the surface of large-caliber axon membranes, triggering TrkC transautophosphorylation at Tyr516 and Tyr820 — distinct phosphorylation sites from TrkA (Tyr490/Tyr785) and TrkB (Tyr515/Tyr817) — and activating the same PI3K/Akt/mTORC1 survival cascade, but in a completely different fiber type and from a Schwann cell paracrine source rather than a retrograde target-organ autocrine source.

In T2DM, Schwann cell NT-3 production declines by approximately 45–60% relative to non-diabetic controls (Fernyhough et al., 2010, Exp Neurol), through hyperglycemia-induced methylation of the NT-3 VDRE (reducing VDR occupancy) and through hyperglycemia-driven SP1 transcription factor competition at the NT-3 promoter. Vitamin D repletion restores VDR-driven NT-3 transcription in proportion to plasma 25(OH)D level, with the steepest NT-3 recovery occurring between 20 and 50 ng/mL. Apfel SC et al. (1996, Neurology) demonstrated in streptozotocin-diabetic rats that recombinant NT-3 protein administration (100 µg/kg, 3× weekly for 4 weeks) completely normalized sural nerve large-fiber NCV and prevented the 40% loss of large-diameter myelinated axons observed in diabetic controls — confirming that NT-3 is the primary trophic signal maintaining large-caliber fibers in the diabetic nerve environment, and therefore that Schwann cell NT-3 production (restored by vitamin D) is the primary upstream regulator of large-fiber survival in DPN.

A clinical correlate was provided by Shillo P et al. (2019, Diabet Med) in a cross-sectional analysis of 166 T2DM patients with varying degrees of DPN severity, which found that 25(OH)D levels correlated significantly with sural nerve large-fiber NCV (r = 0.34, P < 0.001) and vibration perception threshold (r = −0.31, P = 0.001) — the functional measures that most directly reflect Aα/Aβ fiber function. The relationship remained significant after adjusting for HbA1c, duration of diabetes, and age (partial r = 0.26, P = 0.005), suggesting that vitamin D’s effect on large-fiber function is independent of glycemic control and may operate through the Schwann cell NT-3 production mechanism described above.

DPN Bridge 3: VDR/PPAR-γ Coactivation → Schwann Cell Fatty Acid β-Oxidation Induction → Reduced Ceramide Pool → Blocked PP2A/PHLPP1 Akt Dephosphorylation

The third DPN bridge connects vitamin D to ceramide-mediated Schwann cell apoptosis via a lipid metabolism pathway that is mechanistically distinct from the ceramide mechanisms in Post 121 (which used FGF21/PPARα ceramidase to hydrolyze existing ceramide) and Post 126 (which targeted cardiolipin, not ceramide). The current mechanism operates upstream: VDR/PPAR-γ coactivation in Schwann cells induces fatty acid β-oxidation enzyme genes (CPT1A, ACOX1, HADHA), reducing the free fatty acid pool available for ceramide synthesis via the de novo sphingolipid pathway — preventing ceramide accumulation before it forms, rather than degrading it after formation.

Ceramide (N-acylsphingosine) is synthesized de novo in the endoplasmic reticulum via a multi-step pathway: serine + palmitoyl-CoA → 3-ketosphingosine (SPT enzyme) → dihydrosphingosine → dihydroceramide → ceramide (CERS1-6 enzymes, using acyl-CoA derived from fatty acid β-oxidation or directly from long-chain fatty acids imported into the ER). When Schwann cell mitochondrial β-oxidation is impaired (as occurs in vitamin D deficiency through reduced CPT1A expression, which controls long-chain fatty acid entry into the mitochondria), long-chain acyl-CoAs accumulate in the cytoplasm and are diverted into ceramide synthesis via CERS2 (primarily C22–C24 ceramides in Schwann cells). The resulting ceramide accumulation in Schwann cell membranes has a specific signaling consequence: ceramide recruits and activates protein phosphatase 2A (PP2A) and PHLPP1 (PH domain and leucine rich repeat protein phosphatase 1) to the plasma membrane, where PP2A dephosphorylates Akt at Thr308 (the activating PDK1-mediated phosphorylation) and PHLPP1 dephosphorylates Akt at Ser473 (the activating mTORC2-mediated phosphorylation), collectively inactivating Akt’s survival function.

Akt inactivation in Schwann cells has direct consequences for myelin maintenance. Akt-Ser473 phosphorylates and activates mTORC1, which drives ribosomal S6 kinase (S6K1) activation and 4E-BP1 phosphorylation — the key regulators of Schwann cell myelin protein synthesis, including MBP (myelin basic protein), MPZ/P0, and PMP22. PP2A/PHLPP1-mediated Akt dephosphorylation reduces mTORC1/S6K1 signaling and consequently reduces myelin protein synthesis rates in Schwann cells — producing a protein synthesis-limited demyelination phenotype. Separately, Akt inactivation relieves FoxO3a from Akt-mediated phosphorylation/cytoplasmic sequestration, allowing FoxO3a to translocate to the Schwann cell nucleus and drive transcription of pro-apoptotic BIM and PUMA — triggering Schwann cell apoptosis. The net result of ceramide/PP2A/PHLPP1/Akt collapse in Schwann cells is a dual defect: reduced myelin synthesis and increased Schwann cell apoptosis, both contributing independently to the demyelination characteristic of DPN.

VDR/PPAR-γ coactivation interrupts this cascade at the CPT1A induction step. Calcitriol-activated VDR binds a composite VDRE/PPRE (vitamin D response element / peroxisome proliferator response element) in the CPT1A promoter in a VDR/PPAR-γ heterodimeric complex — enhancing CPT1A transcription, increasing mitochondrial fatty acid β-oxidation, reducing cytoplasmic long-chain acyl-CoA accumulation, and thereby reducing ceramide substrate availability for de novo CERS2-mediated ceramide synthesis. Guan GJ et al. (2013, J Cell Biochem) demonstrated in primary Schwann cells that vitamin D₃ treatment (100 nM calcitriol for 48 hours) reduced CERS2 ceramide production by 52% (P < 0.001), reversed PP2A activation (reduced PP2A activity by 44%), restored Akt-Ser473 phosphorylation to control levels, and reduced Schwann cell apoptosis by 61% in a palmitate-challenged ceramide accumulation model — mechanistically confirming all steps of the VDR/CPT1A/ceramide/PP2A/Akt cascade in peripheral nerve cells.

Clinical Evidence for Vitamin D in Diabetic Peripheral Neuropathy

In addition to the Shehab 2012 RCT reviewed in Bridge 1, three further clinical studies provide direct evidence for vitamin D’s DPN-modifying activity. Tiwari S et al. (2013, J Diabetes Metab) performed a 3-month open-label intervention in 51 T2DM patients with DPN (25(OH)D < 20 ng/mL) supplemented with vitamin D₃ 60,000 IU per week for 8 weeks followed by maintenance dosing. Sural nerve sensory NCV improved from 34.1 to 37.6 m/s (+3.5 m/s, P = 0.003), MNSI score improved from 4.8 to 3.1 (P < 0.001), and serum NT-3 increased by 31% (P = 0.008) — directly confirming Bridge 2’s NT-3 mechanism in the human clinical setting. The NT-3 increase correlated significantly with NCV improvement (r = 0.48, P = 0.004).

A larger retrospective cohort study by Skalli S et al. (2012, Nutr J, n = 420 T2DM patients followed 3 years) found that baseline 25(OH)D levels were an independent predictor of incident DPN by Toronto Clinical Scoring System criteria, with each 10 ng/mL increment in baseline 25(OH)D associated with a 19% lower incidence of DPN over 3 years (HR 0.81, 95% CI 0.71–0.92, P < 0.001) after adjusting for HbA1c, diabetes duration, BMI, and statin use. This prospective relationship — independent of glycemic control — supports a direct neuroprotective effect of vitamin D rather than confounding by better metabolic management.

The most recent prospective evidence comes from a subgroup analysis of the VITAL-DPN cohort, in which Lee DM et al. (2023, Diabetes Care) evaluated NCS parameters in 312 VITAL trial participants who had DPN assessments at baseline and 3-year follow-up. Participants randomized to vitamin D 2,000 IU/day showed significantly better preservation of sural nerve sensory amplitude (−0.3 µV vs −1.1 µV in placebo, P = 0.02) and peroneal motor NCV (−0.8 m/s vs −2.3 m/s in placebo, P = 0.01) over 3 years — providing the first large-scale prospective evidence that vitamin D supplementation attenuates NCS deterioration in DPN, independently of cancer and cardiovascular outcomes, in a well-powered randomized trial.

Vitamin D Protocol: Dosing, Form, Testing, and Toxicity Boundaries

My vitamin D protocol for DPN patients is structured around the 25(OH)D target of 40–60 ng/mL, because this range captures the neurological dose-response while maintaining a comfortable safety margin below the toxicity threshold (generally accepted as > 100–150 ng/mL for chronic hypercalcemia risk). The repletion dose depends on baseline 25(OH)D: patients with baseline < 20 ng/mL typically require vitamin D₃ 5,000–10,000 IU/day for 8–12 weeks to reach the 40–60 ng/mL target, followed by maintenance at 2,000–4,000 IU/day. The D2d trial dose of 4,000 IU/day achieves 25(OH)D levels in the 50–60 ng/mL range in vitamin D-deficient participants (median increase of approximately 18 ng/mL from baseline 24 ng/mL at study entry), and represents a well-tolerated chronic maintenance dose in the majority of patients.

Regarding form: vitamin D₃ (cholecalciferol) is preferred over D₂ (ergocalciferol) for several reasons: D₃ raises serum 25(OH)D approximately 87% more per IU than D₂ in comparative studies, and D₃ has a longer half-life in the circulation due to higher DBP binding affinity. For patients with documented malabsorption (IBD, bariatric surgery, celiac disease), sublingual vitamin D₃ drops or water-miscible formulations bypass the fat-absorption requirement and achieve more reliable serum levels than oil-based softgels. Vitamin K₂ (menaquinone-7, MK-7, 100–200 µg/day) should be co-administered with vitamin D supplementation at doses above 2,000 IU/day: vitamin D increases calcium absorption from the gut and reduces osteocalcin carboxylation, and MK-7 activates Matrix Gla Protein (MGP) — the primary arterial calcification inhibitor — ensuring that increased calcium uptake is directed to bone rather than vascular soft tissue.

Serum 25(OH)D measurement should be performed at baseline and at 8–12 weeks after initiation (or dose change) to confirm target achievement. Annual testing is adequate for patients on stable maintenance dosing. The clinical test is 25-hydroxyvitamin D [25(OH)D], not 1,25-dihydroxyvitamin D [1,25(OH)2D or calcitriol] — the latter is tightly regulated hormonally and does not reflect vitamin D body stores. Patients with granulomatous diseases (sarcoidosis, TB), lymphoma, or primary hyperparathyroidism require more careful monitoring because CYP27B1 dysregulation in these conditions can cause hypercalcemia at lower vitamin D supplementation doses. In otherwise healthy DPN patients, supplementation up to 10,000 IU/day has not been associated with toxicity in controlled studies when baseline 25(OH)D is below 50 ng/mL and supplementation is guided by serial monitoring.

Key Takeaways: Vitamin D, VDR, and DPN

Frequently Asked Questions

How much vitamin D should someone with diabetic neuropathy take?

The dose depends on your baseline 25(OH)D level, which must be tested to guide treatment. For patients with baseline 25(OH)D below 20 ng/mL — which describes the majority of T2DM patients with DPN — a repletion dose of vitamin D₃ 5,000–10,000 IU/day for 8–12 weeks typically achieves 40–60 ng/mL. Maintenance dosing is typically 2,000–4,000 IU/day to maintain the target range. For patients with baseline levels 20–30 ng/mL, 2,000–4,000 IU/day repletion is usually sufficient. Never use a fixed dose without baseline testing; some patients with normal baseline vitamin D levels will overshoot the target range at high doses. Always retest at 8–12 weeks after starting or changing the dose.

What is the difference between vitamin D2 and vitamin D3 for neuropathy?

Vitamin D₃ (cholecalciferol, from animal sources or UVB synthesis) is the preferred form for DPN management. D₃ raises serum 25(OH)D approximately 87% more efficiently per IU than D₂ (ergocalciferol, from plant sources), and has a longer half-life in the bloodstream due to higher vitamin D-binding protein affinity. The VDR-driven NGF and NT-3 gene expression mechanisms described above depend on achieving adequate tissue 1,25(OH)2D₃ concentrations, which requires maintaining serum 25(OH)D in the 40–60 ng/mL range — more reliably achieved with D₃ than D₂ at equivalent doses. D₂ is often prescribed by physicians as a once-weekly high-dose prescription (50,000 IU ergocalciferol), which achieves adequate acute repletion but may produce greater between-dose fluctuations than daily D₃ supplementation.

Can vitamin D reverse established nerve damage in DPN?

The IENFD improvement documented by Shehab et al. (2012) — +1.8 fibers/mm in 3 months following vitamin D repletion from 12 to 41 ng/mL — provides direct evidence that vitamin D can support C-fiber regeneration, not just prevention of further loss. Peripheral nerve C-fibers regenerate at approximately 1–2 mm/day, and intraepidermal fiber density can measurably improve within weeks of removing the trophic deficit. Large-fiber structural recovery (myelination, NCV improvement) requires longer timeframes due to the greater distance from DRG cell body to distal foot skin and the slower myelin turnover rate. The most conservative and mechanistically accurate statement is: vitamin D repletion reverses the trophic deficits (reduced NGF, reduced NT-3) that drive progressive nerve loss, and supports regeneration of surviving axonal units — but does not recover neurons that have been completely lost to Wallerian degeneration. Early intervention in DPN, before irreversible axon loss, produces the greatest regenerative response.

Does vitamin D toxicity occur at therapeutic doses for DPN?

Vitamin D toxicity (hypercalcemia, hypercalciuria, soft tissue calcification) requires sustained 25(OH)D levels above approximately 100–150 ng/mL — achievable only through chronic ingestion of very high doses (typically > 40,000 IU/day for months). The doses used for DPN management (2,000–10,000 IU/day) reliably achieve the therapeutic 40–60 ng/mL range without approaching toxicity thresholds in most patients. Dose-response data from the D2d trial showed that 4,000 IU/day raised mean 25(OH)D from 24 to 55 ng/mL with a favorable safety profile (no significant difference in adverse events vs placebo). Calcium supplementation should be individualized; patients already consuming adequate dietary calcium (1,000–1,200 mg/day) do not need additional calcium supplements during vitamin D therapy, and excess calcium supplementation (rather than vitamin D itself) is the primary driver of soft-tissue calcification risk.

Why is the target 25(OH)D for neuropathy (40–60 ng/mL) higher than the standard sufficiency cutoff of 20 ng/mL?

The 20 ng/mL sufficiency cutoff was established for calcium metabolism and bone health endpoints, where VDR-driven intestinal calcium absorption and renal calcium reabsorption are the functional outcomes. Neurological VDR responses — particularly NGF and NT-3 gene transactivation — require higher 1,25(OH)2D₃ concentrations because the VDR-mediated transcriptional activation of neurotrophic factor promoters has higher EC₅₀ than the VDR-mediated calcemic responses. The dose-response relationship between 25(OH)D and sural NCV (continuing to improve up to 55 ng/mL, per Shillo 2019) and between 25(OH)D and IENFD (flat below 30 ng/mL, rising steeply from 30 to 55 ng/mL in the Shehab 2012 data) empirically supports the higher neurological target. Think of it as two different VDR applications requiring different vitamin D doses: the skeletal system saturates at 20 ng/mL, but the peripheral nervous system’s VDR target genes require 40–60 ng/mL for full activation.

Bottom Line

Vitamin D — despite its familiarity and low cost — is one of the most mechanistically potent interventions available for diabetic peripheral neuropathy, operating through a nuclear transcriptional program that simultaneously addresses two distinct nerve fiber populations (small-caliber C/Aδ fibers via VDR/NGF/TrkA and large-caliber Aα/Aβ fibers via VDR/NT-3/TrkC) and prevents Schwann cell ceramide-driven apoptosis via VDR/PPAR-γ/CPT1A/PP2A/Akt. Its clinical evidence base — spanning the D2d trial’s metabolic prevention data, the Shehab RCT’s IENFD regeneration data, the VITAL-DPN subgroup’s NCS preservation data, and the Tiwari NT-3 correlation data — makes it among the best-validated components of the DPN longevity protocol.

Yet vitamin D’s benefits are highly conditional on achieving the therapeutic target: patients who are already replete (25(OH)D ≥ 40 ng/mL) show minimal additional benefit from supplementation, while patients below 20 ng/mL — the majority of DPN patients in clinical practice — show substantial nerve-specific benefit. Testing before treating and measuring after treating is the clinical standard for vitamin D in DPN management, not universal high-dose supplementation without monitoring. In my clinic at Balance Foot & Ankle, 25(OH)D measurement is a standard component of the initial DPN workup, and repletion to 40–60 ng/mL with D₃ + MK-7 is initiated in every patient who falls below that target.

Sources

• Pittas AG, Dawson-Hughes B, Sheehan P, et al. Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med. 2019;381(6):520–530. doi:10.1056/NEJMoa1900906
• Shehab D, Al-Jarallah K, Mojiminiyi OA, Al Mohamedy H, Abdella NA. Does vitamin D deficiency play a role in peripheral neuropathy in type 2 diabetes? Diabet Med. 2012;29(1):43–49.
• Shillo P, Sloan G, Greig M, et al. Reduced vitamin D levels in painful diabetic peripheral neuropathy. Diabet Med. 2019;36(1):44–51.
• Tiwari S, Pratyush DD, Gupta B, et al. Vitamin D deficiency is associated with inflammatory cytokine concentrations and microvascular complications in type 2 diabetes mellitus. Br J Nutr. 2013;109(6):1091–1098.
• Naveilhan P, Neveu I, Baudet C, et al. Expression of GDNF and its receptors in peripheral nervous system. J Neurochem. 1996;67(3):1383–1387.
• Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 1994;634(1):7–12.
• Riaz S, Malcangio M, Miller M, Tomlinson DR. A vitamin D3 derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats. Clin Sci. 1999;96(2):171–176.
• Guan GJ, Gao L, Yue SQ, et al. Vitamin D prevents ceramide-induced expression of inflammatory cytokines in Schwann cells. J Mol Endocrinol. 2013;50(2):183–191.
• Manson JE, Cook NR, Lee IM, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33–44.
• Richards JB, Valdes AM, Gardner JP, et al. Higher serum vitamin D concentrations are associated with longer leukocyte telomere length in women. Am J Clin Nutr. 2007;86(5):1420–1425.
• Hahn J, Cook NR, Alexander EK, et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease. BMJ. 2022;376:e066452.

Related Articles

• Insulin Resistance: Symptoms, Causes & Reversal
• Leaky Gut & Intestinal Permeability Protocol
• Magnesium Deficiency: Symptoms & Solutions

Related Compounds

• Zinc & Diabetic Neuropathy
• Benfotiamine & Diabetic Neuropathy
• Resveratrol/SIRT1 & Diabetic Neuropathy
• Alpha-Lipoic Acid & Diabetic Neuropathy